Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Alendronate Sodium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

47 API Suppliers, 24 USDMF, 13 CEP/COS, 6 JDMF, 10 EU WC, 13 KDMF, 11 NDC API, 19 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

234 FDF Dossiers, 64 FDA Orange Book, 107 Europe, 24 Canada, 8 Australia, 3 South Africa, 28 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 70MG BASE, TABLET;ORAL - EQ 70MG BASE;2,800 IU, TABLET;ORAL - EQ 70MG BASE;5,600 IU

RELATED EXCIPIENT COMPANIES

4 Rochem International Inc, 18 SPI Pharma, 6 DKSH, 1 Pharm-RX Chemical, 7 Faran Shimi Pharmaceutical, 3 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 1 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 2 Actylis, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 BASF, 1 Bioplus Life Sciences, 7 DFE Pharma, 5 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 26 Kerry, 3 Lonza Capsugel, 12 Microlex e.U, 2 Pharmatrans-Sanaq, 7 Pluviaendo, 4 Prachin Chemical, 1 Qualicaps, 18 Roquette, 1 Seppic, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 1 Ulanqab Kema New Material, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders, 29 Disintegrants & Superdisintegrants, 28 Direct Compression, 24 Taste Masking, 19 Thickeners and Stabilizers, 19 Granulation, 17 Co-Processed Excipients, 15 Chewable & Orodispersible Aids, 14 Lubricants & Glidants, 8 Empty Capsules, 7 Coating Systems & Additives, 6 Parenteral, 5 Controlled & Modified Release, 3 Emulsifying Agents, 3 API Stability Enhancers, 3 Solubilizers, 2 Topical, 2 Rheology Modifiers, 1 Surfactant & Foaming Agents, 1 Film Formers & Plasticizers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 25 News #PharmaBuzz

GLOBAL SALES INFORMATION

4 US Medicaid Prescriptions, 120 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

10 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

1 US Patents, 17 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 4 JP, 1 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/03/2025	Polpharma	Poland	Hwail Pharmaceutical Co., Ltd.	20181023-209-J-116	alendronate sodium hydrate	2018-10-23	Pharmaceutical Works Polpharma S.A.	Poland	19, Pelplinska Str. 83-200 Starogard Gdanski, Poland
28/03/2025	Polpharma	Poland	Korea United Pharmaceutical Co., Ltd.	20181023-209-J-116(2)	alendronate sodium hydrate	2019-08-29	Pharmaceutical Works Polpharma S.A.	Poland	19. Pelplinska Str, 83-200 Starogard Gdanski, Poland

Alendronate Sodium

Alendronate Sodium

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

47 API Suppliers

24 USDMF

13 CEP/COS

6 JDMF

10 EU WC

13 KDMF

11 NDC API

19 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

234 FDF Dossiers

64 FDA Orange Book

107 Europe

24 Canada

8 Australia

3 South Africa

28 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 35MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 40MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 70MG BASE

TABLET;ORAL - EQ 70MG BASE;2,800 IU

TABLET;ORAL - EQ 70MG BASE;5,600 IU

RELATED EXCIPIENT COMPANIES

4 Rochem International Inc

18 SPI Pharma

6 DKSH

1 Pharm-RX Chemical

7 Faran Shimi Pharmaceutical

3 Boai NKY Pharmaceuticals Ltd

8 Gangwal Healthcare

1 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 ACG Worldwide

2 Actylis

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

7 BASF

1 Bioplus Life Sciences

7 DFE Pharma

5 Gangwal Chemicals

1 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

26 Kerry

3 Lonza Capsugel

12 Microlex e.U

2 Pharmatrans-Sanaq

7 Pluviaendo

4 Prachin Chemical

1 Qualicaps

18 Roquette

1 Seppic

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

11 Sigachi Industries

1 Ulanqab Kema New Material

4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

75 Fillers, Diluents & Binders

29 Disintegrants & Superdisintegrants

28 Direct Compression

24 Taste Masking

19 Thickeners and Stabilizers

19 Granulation

17 Co-Processed Excipients

15 Chewable & Orodispersible Aids

14 Lubricants & Glidants

8 Empty Capsules

7 Coating Systems & Additives

TABLET;ORAL - EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 35MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 40MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons